Ibogaine Clinical Trials Now Recruiting in the United States: A ClinicalTrials.gov Guide (2026)

For years, anyone searching ClinicalTrials.gov for ibogaine studies recruiting in the United States came up nearly empty. Ibogaine's Schedule I status made domestic human research almost impossible, and the handful of registered studies were observational, international, or long since completed. That has changed. In 2026, U.S. institutions are actively recruiting participants for ibogaine research — a milestone decades in the making.

This guide explains how to search ClinicalTrials.gov for recruiting ibogaine studies, what the flagship trial NCT07226570 involves, who qualifies, and what to do if a trial isn't the right fit. For ongoing updates on every registered study, our team maintains a continuously updated ibogaine research hub tracking ClinicalTrials.gov recruiting studies that summarizes each trial's status, location, and eligibility criteria in plain language.

Why U.S. Ibogaine Trials Matter Now

Ibogaine — a naturally occurring alkaloid derived from the root bark of Tabernanthe iboga — has shown remarkable promise for interrupting opioid dependence and easing withdrawal, often within a single treatment session. Observational data from clinics abroad, along with Stanford's widely cited study of veterans with traumatic brain injury, pushed ibogaine from the fringes of drug policy into serious academic medicine.

The turning point came from two directions:

1. State funding. Texas committed $50 million to ibogaine clinical research, the largest public investment in a psychedelic-adjacent therapy in U.S. history, with Kentucky and Colorado exploring similar initiatives.
2. Federal openness. The FDA has granted investigational new drug (IND) clearances allowing carefully controlled human ibogaine studies on American soil, with cardiac monitoring protocols addressing the compound's known QT-prolongation risk.

The result: for the first time, typing "ibogaine" into ClinicalTrials.gov and filtering for "Recruiting" and "United States" returns active interventional and observational studies.

How to Search ClinicalTrials.gov for Recruiting Ibogaine Studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies. Here's the fastest way to find ibogaine trials currently enrolling:

1. Go to clinicaltrials.gov and enter "ibogaine" in the condition/intervention search field.
2. Under Study Status, check "Recruiting" (you can also include "Not yet recruiting" to see upcoming studies).
3. Under Location, select United States — or enter your state directly.
4. Sort by "Last Update Posted" to see the most recently active listings first.

Each study page lists an NCT number (the unique registry identifier), the sponsoring institution, enrollment targets, inclusion and exclusion criteria, and contact information for the study coordinator. Always contact the coordinator directly — recruitment status on the registry can lag behind reality by weeks.

Reading a Trial Listing: What Actually Matters

• NCT number — cite this when you call or email; coordinators handle multiple studies.
• Eligibility criteria — pay close attention to cardiac exclusions (QT interval, structural heart disease), current medications (especially SSRIs and methadone), and substance-use requirements.
• Study type — interventional trials administer ibogaine; observational studies may only track people who receive treatment elsewhere.
• Locations and contacts — many U.S. ibogaine studies recruit regionally, so check whether travel and lodging are supported.

Spotlight: NCT07226570 — Mapping Ibogaine Neural Dynamics in Opioid Use Disorder

The study generating the most search interest right now is NCT07226570, "Mapping Ibogaine Neural Dynamics in Opioid Use Disorder," currently listed as recruiting. This trial is designed to answer a question that has hovered over ibogaine research for decades: what exactly does ibogaine do to the brain when it interrupts opioid dependence?

Key features of the study design:

• Population: Adults with opioid use disorder (OUD), including those using fentanyl, heroin, or prescription opioids.
• Focus: Neuroimaging and electrophysiological mapping of brain network changes before, during, and after ibogaine administration — the "neural dynamics" in the study's title.
• Why it matters: Prior evidence suggests ibogaine promotes neuroplasticity, resets opioid tolerance, and quiets the brain circuits driving craving. Direct human neural data would move those claims from hypothesis to documented mechanism, strengthening the case for FDA approval pathways.

Searchers in the Upper Midwest — Minnesota, Wisconsin, Iowa, North Dakota, and South Dakota — have been especially active in looking for regional recruitment sites, reflecting how hard the opioid crisis has hit rural counties in those states. Trial site availability changes as studies add locations, so check the NCT07226570 listing's "Contacts and Locations" section regularly, or follow the state-by-state recruitment summaries on the MindScape Retreat ibogaine research hub, which we update as new sites come online.

Who Qualifies for Ibogaine Trials — and Who Doesn't

Ibogaine trials apply some of the strictest screening in addiction research, because ibogaine affects cardiac ion channels and can prolong the QT interval. Expect exclusions or extra screening for:

• Cardiac conditions: long QT syndrome, arrhythmias, structural heart disease, or a family history of sudden cardiac death. Every legitimate protocol requires a baseline ECG.
• Medication conflicts: SSRIs, SNRIs, methadone, and other QT-prolonging or serotonergic drugs typically require supervised tapering before dosing.
• Electrolyte abnormalities: low potassium or magnesium amplify cardiac risk and must be corrected first.
• Psychiatric exclusions: active psychosis or bipolar I disorder commonly disqualify participants, consistent with psychedelic research norms.

If you're screened out of a trial, that isn't a verdict on whether ibogaine could ever be appropriate for you — it reflects the deliberately narrow criteria of early-phase research. Understanding how ibogaine works on the brain's addiction circuitry can help you evaluate whether pursuing treatment through other legal channels makes sense.

What Trial Participation Involves

Participants in interventional ibogaine studies should expect a process far more involved than a typical drug trial:

1. Screening (1–4 weeks): medical history, ECG, bloodwork, psychiatric evaluation, and substance-use assessment.
2. Stabilization: short-acting opioid transition for participants on methadone or buprenorphine, since long-acting opioids complicate ibogaine dosing.
3. Dosing day: continuous cardiac telemetry, IV access, and physician supervision for 24+ hours. The acute experience typically lasts 8–12 hours.
4. Follow-up: neuroimaging sessions, craving and withdrawal assessments, and check-ins that may extend 6–12 months.

Trials cover the cost of treatment and monitoring, which is significant — but participation also means accepting randomization, extensive data collection, and travel to study sites.

If You Can't Wait for a Trial

Recruiting studies enroll dozens of participants; the opioid crisis affects millions. Many people researching ClinicalTrials.gov listings ultimately conclude that trial timelines, eligibility restrictions, or geography make participation unrealistic.

Medically supervised ibogaine treatment remains legally available outside the United States. Mexico has become the leading destination, with established clinics operating under physician oversight with cardiac screening protocols mirroring those used in formal research. If you're considering this route, vet providers with the same rigor a trial would apply to you — insist on pre-treatment ECG screening, on-site emergency equipment, and licensed medical staff. Our guide to choosing an ibogaine treatment clinic covers the specific safety credentials to demand, and the physician-supervised ibogaine treatment program at MindScape Retreat in Cozumel follows research-grade cardiac monitoring standards for every patient.

How the U.S. Trial Landscape Is Likely to Evolve

Reading the registry today only tells you part of the story. Several signals suggest the recruiting list will grow substantially through 2026 and 2027:

• Texas's $50 million program is structured to fund multiple FDA-track trials, not a single study. As those protocols clear IRB review, expect new NCT registrations with Texas-based sites, likely targeting opioid use disorder and veteran populations first.
• Veteran advocacy is driving bipartisan momentum. The Stanford data on special-operations veterans made ibogaine a rare drug-policy issue with support across party lines, and congressional interest in psychedelic research for PTSD and TBI continues to expand the funding pipeline.
• Academic medical centers are building capacity. Institutions that spent years observing from the sidelines are now hiring investigators with psychedelic-trial experience, setting up the cardiac-monitoring infrastructure ibogaine studies require.

Practically, this means that if you search today and find nothing within reach, search again next quarter. Set up a free ClinicalTrials.gov account and save your search — the registry can email you when new ibogaine studies post or when existing studies add recruiting locations. Pair that with periodic checks of curated summaries like our ibogaine research articles library, which translates new registrations and published findings into plain-English updates.

Frequently Asked Questions

Are there ibogaine clinical trials recruiting in the United States right now? Yes. As of 2026, ClinicalTrials.gov lists active ibogaine studies recruiting U.S. participants, including NCT07226570 on ibogaine neural dynamics in opioid use disorder. Search "ibogaine" with the "Recruiting" status filter and U.S. location filter for the current list.

Is ibogaine legal in the United States? Ibogaine remains a Schedule I substance federally, which is why treatment access is limited to registered clinical trials domestically. Outside trials, treatment is legal in countries such as Mexico and New Zealand.

Do trials pay for ibogaine treatment? Interventional trials cover treatment and monitoring costs, and some compensate for time and travel. They do not function as free treatment programs, however — randomization and research procedures are part of participation.

How do I know if a trial is legitimate? Every legitimate U.S. study appears on ClinicalTrials.gov with an NCT number, a named sponsor institution, and IRB oversight. Be skeptical of any "trial" that charges participants for the investigational drug.

The Bottom Line

The phrase "clinicaltrials.gov ibogaine recruiting united states" went from a dead-end search to a live pipeline of American research in under two years. NCT07226570 and the studies following it will determine whether ibogaine becomes an FDA-sanctioned treatment for opioid use disorder — and the data generated in the next 24 months will shape that answer.

Whether you're a potential participant, a clinician, or a family member researching options, stay current: bookmark the ibogaine research hub for tracked updates on every recruiting study, new NCT registrations, and state-by-state site availability as U.S. ibogaine research accelerates.